Is MKC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Unilever Foods combination, with revenue (ttm) at ~$7.39B. The bear case rests on the core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S. Analysts covering it are spread from $52.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $52.00, +5.9% from the $49.09 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Unilever Foods combination. Under the March 2026 agreement, Unilever's Foods business separates and merges with McCormick, with Unilever shareholders expected to hold ~55.1% of the combined company, existing McCormick shareholders ~35.0% and Unilever itself ~9.9%, plus a one-time ~$15.7 billion cash payment to Unilever. The most optimistic analyst target on MKC is $75.00, +52.8% from the $49.09 price. That figure is only reachable if this thesis works close to its best case.

The core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S. spices to cheaper private-label and store-brand alternatives after several years of aggressive pricing. GLP-1 weight-loss medications are an additional structural question for the whole packaged-food category, since lower calorie intake across a population reduces the volume base even if flavor intensity per meal rises. The Unilever Foods merger carries the largest single set of risks: a shareholder vote that has not yet happened, a UK antitrust review, expected net leverage of ~4.0x or less at close, and the integration of a business far larger than McCormick into a company that has never operated at that scale, with existing McCormick holders diluted to ~35% of the result. Commodity costs, currency and trade policy have all moved margins around in both directions this year, and the ~$28 million tariff refund that helped the second quarter illustrates how much of recent margin expansion is timing rather than trend. Finally, an M&A fairness investigation by plaintiffs' firms was announced in April 2026 in connection with the merger terms, which is routine for a deal of this size but is one more source of delay. The most pessimistic published target is $52.00, +5.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Spice and flavor maker behind McCormick, French's, Frank's RedHot, Lawry's and Old Bay, selling to grocery shoppers and, through Flavor Solutions, to food manufacturers.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Unilever Foods combination) stalling in the reported numbers rather than in the narrative, the risk above (the core problem is that organic growth is roughly 1% to 3% and Consumer volumes in the Americas have been flat to slightly negative, with commentary from analysts pointing to share loss in U.S) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

McCormick trades on the New York Stock Exchange, so any brokerage account offering U.S. equities can hold it, including accounts supporting fractional shares. MKC is the non-voting share class and the one included in the S&P 500 and in most index funds, with roughly 254.1 million shares outstanding as of May 31, 2026. Shares traded around ~$49 in late September 2026 for a market value of about ~$13.2 billion across all ~268.9 million shares.

McCormick has two classes listed on the NYSE. MKC is Common Stock Non-Voting, about 254.1 million shares, and is the liquid line that index funds and most investors own. MKC.V is the voting Common Stock, only about 14.8 million shares, held largely by employees, retirees and others closely associated with the company. Both classes receive the same dividend and rank equally on any liquidation, so the practical difference is voting rights and trading liquidity, not economics.

Because trailing earnings contain a one-time item. Trailing twelve-month EPS of ~$6.01 includes a non-cash gain of ~$3.22 per share recorded in the first quarter of fiscal 2026, when McCormick's previously held 50% stake in McCormick de Mexico was remeasured to fair value as the joint venture was consolidated at 75% ownership. Stripping that out, fiscal 2026 adjusted EPS guidance of ~$3.05 to ~$3.13 against a ~$49 share price is closer to ~16x, which is the more representative figure.